Skip to main content

Table 1 Mean (± sem) percent of control after chronic of treatment with EVP-0015962 at 20 or 60 mg/kg/day

From: Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice

  Neocortex Hippocampus
Stain and pathology Control EVP-0015962 (mg/kg/day) Control EVP-0015962 (mg/kg/day)
Parameter diet 20 60 diet 20 60
6E10 immunostaining of Aβ plaque pathology   
 Percent area 100 (10.8) 69.2 (9.7) 65.3 (16.3) 100 (10.8) 62.1 (13.2)* 53.1 (15.2)*
 Number/mm2 100 (7.9) 65.2 (8.8) 71.3 (15.0) 100 (9.7) 61.0 (12.2)* 53.9 (16.8)*
 Size (μm2) 100 (6.5) 105.5 (8.8) 88.5 (5.4) 100 (16.4) 99.4 (15.7) 104.1 (11.6)
ThioflavinS staining of Aβ plaque pathology   
 Percent area 100 (18.0) 64.3 (14.3) 29.9 (7.3)* 100 (14.7) 40.7 (16.9)** 27.3 (6.5)**
 Number/mm2 100 (12.4) 64.3 (8.0) 59.6 (14.1) 100 (12.7) 55.2 (15.6)* 50.7 (12.8)*
 Size (μm2) 100 (8.5) 87.8 (12.2) 58.1 (10.6)* 100 (6.8) 56.5 (16.3) 58.9 (27.0)
GFAP immunostaining of reactive astrocytes   
 Percent area 100 (12.5) 95.8 (14.5) 61.6 (7.6) 100 (9.0) 95.8 (7.7) 87.2 (9.7)
CD11b immunostaining of activated microglia   
 Percent area 100 (12.8) 86.3 (5.0) 66.2 (7.7) 100 (12.1) 69.8 (9.2) 61.8 (10.7)
  1. *p<0.05, **p<0.01 compared with Tg2576 mice on control diet by 1-way ANOVAs and post-hoc Newman-Keuls tests.
  2. N = 9 mice in the control diet group and 6 in the EVP-0015962 treatment groups.